Biotechnology
Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer
SHANGHAI and HONG KONG, June 8, 2020 /PRNewswire/ -- Antengene Corporation
(Antengene) today announced its appointment of Mr.Donald Lung as Chief
Financial Officer (CFO), effectiveJune 8, 2020. Donald will report directly to
Dr.Jay Mei, Chairman and CEO of Antengene.
2020-06-08 20:00
1988
Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020
SONGDO, South Korea, June 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week. As the biopharmaceutical industry's largest event, BIO International Convention brings together over 17,000 indu...
2020-06-08 19:00
1628
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593),Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are next-generation iPS cells created with gene-editing technology to engineer a low risk of immune r...
2020-06-05 13:00
1993
PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas
DAEJEON, South Korea, June 3, 2020 /PRNewswire/ -- PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm ("Wincal"), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the c...
2020-06-04 00:00
1397
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
Key Highlights * TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need * A marketing application has now been accepted by the TGA under provisional evaluation pathway * Lurbinectedin has received priority review u...
2020-06-03 14:30
1327
Firmenich Appoints Boet Brinkgreve as President Ingredients
GENEVA, June 2, 2020 /PRNewswire/ -- In order to strengthen Firmenich industry leadership in ingredients and drive a new era of excellence, Firmenich, has appointed Boet Brinkgreve to President of Ingredients, effectiveJune 1st, 2020. Boet will continue to report directly to Firmenich CEO,Gilbert...
2020-06-02 23:41
1689
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced ...
2020-06-01 07:30
1659
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research results of TY...
2020-06-01 07:30
1741
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT® (sin...
2020-06-01 07:30
2448
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
SUZHOU, China and ROCKVILLE, Md., May 31, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company presented fo...
2020-05-31 20:00
2055
I-Mab Announces Upcoming Participation at June Conferences
SHANGHAI and GAITHERSBURG, Md., May 29, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical ...
2020-05-29 20:00
5961
Seaweed Extract Offers Hope for Influenza A
CAMBRIDGE, Australia, May 28, 2020 /PRNewswire/ -- Australian scientists have revealed that a natural compound found in seaweed may reduce the effects of severe cases of Influenza A. Fucoidan is a highly bioactive compound found naturally in brown seaweed and well known for its diverse therapeu...
2020-05-28 15:30
1019
IntegriCulture Inc. Closes Series A Fundraising Round Led by Beyond Next Ventures at JPY800 Million
TOKYO, May 28, 2020 /PRNewswire/ -- IntegriCulture Inc. has completed a Series A fundraising round ofJPY800 million (USD7.4 million) backed by Beyond Next Ventures, NH Foods, AgFunder and other investors. The cumulative amount raised stands aboutJPY1.1 billion (USD10.2 million). (Logo: https://...
2020-05-28 13:00
1911
Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies
SUZHOU, China, May 27, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery,development and manufacturing of antibody-based therapeutics, announced today results reported for the first time from a Phase 1...
2020-05-27 23:00
1086
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets
AMBLER, Pa., May 25, 2020 /PRNewswire/ -- Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's Du...
2020-05-25 22:00
1411
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
LONDON and SONGDO, South Korea, May 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. Under the terms of th...
2020-05-22 07:11
6275
Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II
SUZHOU, China, May 21, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announced that it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal ...
2020-05-21 23:00
1415
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan"), China Biolog...
2020-05-21 04:45
11209
China Biologic Reports Financial Results for the First Quarter of 2020
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the first quarter of 2020. First Quarter ...
2020-05-21 04:30
10517
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 20, 2020 /PRNewswire/ -- VolitionRx Limited
2020-05-20 20:45
10730
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5482
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4443
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4034
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3294
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3039